DBT–BIRAC Host 12th Webinar on Cell & Gene Therapy Advancements
Technology

DBT–BIRAC Host 12th Webinar on Cell & Gene Therapy Advancements

The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around “Cell and Gene Therapy”, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024.

With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing.

Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility.

Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development.

Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible.

Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around “Cell and Gene Therapy”, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024. With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing. Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility. Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development. Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible. Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

Next Story
Real Estate

K Raheja Corp launches luxury tower at Raheja Galaxy, South Pune

K Raheja Corp Homes has unveiled a new luxury tower at Raheja Galaxy in South Pune, catering to the growing demand for premium living spaces in the area. Located off NIBM, the project offers seamless connectivity, excellent infrastructure, and a reputation for timely delivery and superior construction quality.The new tower features spacious 2-bed, 3-bed, and 3BHK L residences, priced from Rs 1.29 crore. The homes are designed with modern amenities and a neo-classical architectural style, offering a balance of functionality and luxury. Prices will increase after April 30th, making the early-bir..

Next Story
Infrastructure Urban

PM to Visit Bihar on April 24 for Panchayati Raj Day Celebrations

Prime Minister Shri Narendra Modi is scheduled to visit Bihar on 24th April 2025. During his visit to Madhubani, he will participate in the National Panchayati Raj Day celebrations at around 11:45 AM. On this occasion, he will inaugurate, dedicate, and lay the foundation stone for several development projects worth over Rs 134 bn, and will address the public gathering. As part of the programme, the Prime Minister will present the National Panchayat Awards, honouring the best-performing Panchayats from across the country. In the railways sector, Prime Minister Modi will flag off the Amrit Bha..

Next Story
Infrastructure Urban

Rs 140 Bn Infra Projects in North India Reviewed by DPIIT Secretary

Shri Amardeep Bhatia, Secretary of the Department for Promotion of Industry and Internal Trade (DPIIT), chaired a high-level Project Monitoring Group (PMG) review meeting to assess progress on major infrastructure projects in Uttar Pradesh, Haryana, Punjab, and Uttarakhand. The meeting was attended by senior officials from central ministries, state governments, and private sector project proponents. A total of 17 key infrastructure projects, collectively worth over Rs 140 billion, were reviewed during the session, which addressed 19 critical issues affecting project execution. The discussions..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?